CNS Pharma's Cancer Drug Misses Survival Goal But May Offer Fewer Side Effects

CNS Pharmaceuticals, Inc. CNSP on Tuesday announced the primary analysis of its clinical trial evaluating Berubicin for recurrent or progressive Glioblastoma Multiforme (GBM), an aggressive form of brain cancer.The trial compared Berubicin to Lomustine, a current standard of care in recurrent or progressive GBM.This analysis did not demonstrate statistically significant superiority in overall survival, the primary endpoint.Additionally, patients experienced no cardiotoxicity, a risk that curtails the use of ...